Dorzolamide

Dorzolamide is a carbonic anhydrase inhibitor. It is an anti-glaucoma agent and topically applied in the form of eye drops. This drug was the first drug in human therapy (market introduction 1995) which resulted from structure-based drug design.

Additional recommended knowledge

Guide to balance cleaning: 8 simple steps

Essential Laboratory Skills Guide

Safe Weighing Range Ensures Accurate Results

Trusopt (dorzolamide hydrochloride ophthalmic solution) is a carbonic anhydrase inhibitor formulated for topical ophthalmic use. Trusopt is used to lower increased intraocular pressure in open-angle glaucoma and ocular hypertension.

References

• Kubinyi H (1999). "Chance favors the prepared mind--from serendipity to rational drug design". J Recept Signal Transduct Res 19 (1-4): 15-39. PMID 10071748.
• Plummer C, MacKay E, Gelatt K. "Comparison of the effects of topical administration of a fixed combination of dorzolamide-timolol to monotherapy with timolol or dorzolamide on IOP, pupil size, and heart rate in glaucomatous dogs.". Vet Ophthalmol 9 (4): 245-9. PMID 16771760.
• Grover S, Apushkin M, Fishman G (2006). "Topical dorzolamide for the treatment of cystoid macular edema in patients with retinitis pigmentosa.". Am J Ophthalmol 141 (5): 850-8. PMID 16546110.
• Almeida G, Faria e Souza S (2006). "Effect of topical dorzolamide on rabbit central corneal thickness.". Braz J Med Biol Res 39 (2): 277-81. PMID 16470316.